SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. – Trademark Portfolio
Entity Type: 99
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include LUOXIN PHARMACEUTICAL. The owner is based in Shandong.
Luo 7 Road
High & New Technology Industries Development Zone, Linyi
Shandong 276017 , CN
Showing of trademarks Trademarks
Trademark Classifications
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. have?
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. file in?
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.'s most well-known trademarks?
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.'s registered trademark portfolio includes well-known marks such as LUOXIN PHARMACEUTICAL. These are among 1 currently registered trademark in the portfolio.
What is SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.'s trademark registration success rate?
SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.